MetaCap

Seres Therapeutics Inc. (MCRB)

NASDAQ: MCRBHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.24-0.09 (-6.77%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MCRB stock chart

Technical analysis

Key statistics

All statistics
Market cap
$12.64M
EPS (TTM)
-$5.01
52-week range
1.20 – 18.86
Day range
1.20 – 1.36
Volume / Avg
56.76K / 74.83K
Beta
—

52-week range

$1.20$18.86

MCRB stock today

Seres Therapeutics (MCRB) closed at $1.24 on Nov 20, down 6.77% (-$0.09), versus the S&P 500's 3.70% decline. At this level, MCRB sits near the bottom of its 52-week range of $1.20 to $18.86: 93.4% below the high and 3.2% above the low. Seres Therapeutics has posted a net loss over the last twelve months (EPS of -$5.01), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Seres Therapeutics

Company profile

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Richard N. Kender B.S., M.B.A.
Headquarters
Cambridge, MA
Employees
66
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, Seres Therapeutics generated $789,000 in revenue, up 0.0% from fiscal 2024. Net income was $5.7 million (+4088.2% year over year), for a net margin of 721.9% versus a median of -268.3% in the prior 5 years. Operating margin was -11910.1%.

Seres Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$789.00K$0$0$7.13M$144.93M
Growth——-100.00%-95.08%+336.33%
Net income$5.70M$136.00K$-113.72M$-250.16M$-65.58M
EPS (diluted)$0.64$0.00$-17.77$-2.31$-0.72

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$17.00+1270.97%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $22.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-1.63 vs $-1.34
Surprise
-21.64%

MCRB news

All MCRB news

Seres Therapeutics peers

Health Care sector
MCRB peer companies
CompanyPrice% ChgMarket capCompare
NEUPNeuphoria Therapeutics Inc.2.35+1.29%$12.72Mvs MCRB
ALLRAllarity Therapeutics Inc.0.785-9.25%$12.56Mvs MCRB
BOLTBolt Biotherapeutics Inc.4.91-2.96%$12.80Mvs MCRB
MIRAMIRA Pharmaceuticals Inc.0.291-20.84%$12.23Mvs MCRB
TVRDTvardi Therapeutics Inc.0.9893+4.57%$13.22Mvs MCRB
ACTUActuate Therapeutics Inc.0.2253+5.38%$13.60Mvs MCRB
BYSIBeyondSpring Inc.0.33-24.49%$13.66Mvs MCRB
CTXRCitius Pharmaceuticals Inc.0.5085+2.27%$13.96Mvs MCRB

Indexes, lists and sector

Seres Therapeutics stock FAQ

What is Seres Therapeutics's stock price today?

MCRB last traded at $1.24 as of Nov 20, 4:00 PM EST, down 6.77% on the day. Prices are delayed at least 15 minutes.

Who is Seres Therapeutics's CEO?

Mr. Richard N. Kender B.S., M.B.A. is the chief executive officer of Seres Therapeutics Inc., which has about 66 employees.

What is the MCRB 52-week high?

The 52-week high for MCRB is $18.86 and the 52-week low is $1.20. The stock is currently 93.4% below its high.

Compare MCRB